Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. (CRDF) is asking stockholders at a special meeting on October 22, 2026 to approve an amendment to its Amended and Restated Certificate of Incorporation to increase authorized capital stock from 170,000,000 to 320,000,000 shares and authorized common stock from 150,000,000 to 300,000,000. Authorized preferred stock remains 20,000,000 shares.
The board states this increase is intended to provide flexibility for future uses, including potential partnerships, acquisitions, financings (such as offerings under a $400 million universal shelf registration and a $150 million Open Market Sale Agreement with Jefferies), equity incentive plans, and other corporate purposes. As of August 26, 2026, there were 77,795,249 common shares outstanding, plus additional shares reserved or issuable under warrants, options, equity plans and preferred stock.
Cardiff notes that issuing additional shares could dilute earnings per share and existing stockholders’ equity and voting rights, and could make a change of control more difficult, while stating the proposal is not being made as an anti-takeover measure. A second proposal would allow adjournment of the meeting to solicit more proxies if there are insufficient votes to approve the amendment.
Cardiff Oncology, Inc. is asking stockholders at a special meeting in October 2026 to approve an amendment to its Amended and Restated Certificate of Incorporation to increase authorized capital stock from 170,000,000 to 320,000,000 shares, including an increase in authorized common stock from 150,000,000 to 300,000,000 shares, while keeping authorized preferred stock at 20,000,000 shares. The additional common shares would have the same rights as existing common stock and could be issued for financings, strategic transactions, equity incentives, warrant exercises, and other corporate purposes, including potential use under an existing $400 million universal shelf registration and a $150 million at-the-market offering program with Jefferies LLC.
The company notes that issuing additional common stock in the future could dilute existing stockholders’ ownership and voting power and could affect the trading price of the shares, though no specific new issuances are currently planned beyond existing agreements and plans. A second proposal would authorize adjournment of the special meeting, if needed, to solicit additional proxies in support of the share increase. The board of directors unanimously recommends voting “FOR” both proposals.
Cardiff Oncology, Inc. reported continued operating losses while progressing its lead PLK1 inhibitor, onvansertib, through Phase 2 development in RAS-mutated metastatic colorectal cancer and other investigator-initiated trials. For the quarter ended June 30, 2026, royalty revenue was $104,000 and net loss was $9.2 million, compared with $13.9 million a year earlier, as research and development expenses fell to $5.9 million from $11.6 million due to trial completions and reduced preclinical work.
For the first six months of 2026, net loss was $21.6 million and operating cash outflows were $24.1 million. As of June 30, 2026, Cardiff held $34.5 million in cash, cash equivalents and short-term investments and disclosed that this is not sufficient to meet funding requirements for at least 12 months after issuance, leading management to conclude there is substantial doubt about its ability to continue as a going concern. Subsequent to quarter-end, the company raised $10.1 million in gross proceeds via a registered direct offering of common stock and warrants. Cardiff also highlighted ongoing litigation with its onvansertib licensor NMS regarding alleged termination of the license agreement, noting that an adverse outcome could materially impact its business.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Cardiff Oncology, Inc. common stock. BlackRock reports beneficial ownership of 863,259 shares of common stock, representing 1.3% of the class as of the reporting date.
BlackRock has sole voting power and sole dispositive power over all 863,259 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have economic interests in these shares, but no single person has more than 5% of Cardiff Oncology’s outstanding common stock.
Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases dated 2026-07-14 of 687,285 shares of common stock at $1.455 per share and 687,285 common stock purchase warrants with an exercise price of $1.33 per share. Following these transactions he holds 2,043,661 common shares directly plus 687,285 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and remain exercisable for five and one-half years after that Initial Exercise Date.
Cardiff Oncology, Inc. director and Chief Executive Officer Mani Mohindru reported open-market purchases on July 14, 2026. She bought 34,364 shares of Common Stock at $1.455 per share and acquired 34,364 Common Stock Purchase Warrants exercisable at $1.33 per share. After these transactions, she holds 59,067 Common Shares directly and 34,364 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and have a term of exercise of five and one-half years after the Initial Exercise Date.
Cardiff Oncology entered into definitive agreements for a registered direct offering of 8,571,429 shares of common stock and accompanying warrants to purchase 8,571,429 shares, at $1.05 per share and warrant, pursuant to its shelf registration statement on Form S-3. Certain officers and directors are also purchasing additional shares and warrants at a higher per-share price.
The warrants have an exercise price of $1.31 per share for outside investors and $1.33 for insiders, become exercisable six months after issuance and after an authorized share increase, and expire five and one-half years after that date. Gross proceeds are approximately $10.05 million, to be used for working capital and general corporate purposes. H.C. Wainwright & Co. acts as exclusive placement agent, earning a 7.0% cash fee and a warrant for 465,157 shares at $1.3125 per share. Cardiff Oncology will seek stockholder approval to increase authorized common shares, committing to file a proxy within 45 days of closing and to hold repeated meetings until approval is obtained or the warrants are no longer outstanding.
Cardiff Oncology, Inc. is offering 9,293,078 shares of common stock with accompanying warrants to purchase 9,293,078 shares, for aggregate gross proceeds of $10,050,000 in a best-efforts public offering. H.C. Wainwright will receive a 7.0% cash fee and 464,654 placement agent warrants.
The common warrants have an exercise price of $1.31 per share ($1.33 for insiders), become exercisable six months after issuance and after an authorized share increase is approved, and run for five and one-half years. Cardiff expects net proceeds of about $9.1 million, to fund continuing operating expenses and working capital. Shares outstanding will be 77,795,248 immediately after the offering, excluding warrant exercises. Based on an effective price of $1.08, net tangible book value would increase from $0.51 to $0.56 per share, causing immediate dilution of about $0.52 per share to new investors. The warrants include 4.99% (or 9.99%) beneficial ownership limits and will not be listed, and the company’s auditors have included an explanatory paragraph regarding its ability to continue as a going concern.
Cardiff Oncology CEO Mani Mohindru reported an open-market purchase of 24,703 shares of Common Stock at $1.21 per share. This transaction took place on June 18, 2026 and represents a direct holding. Following the trade, her reported direct ownership totals 24,703 shares.